Efficacy of COVID-19 vaccines: From clinical trials to real life.
Efficacy of COVID-19 vaccines: From clinical trials to real life.
复制标题
DOI：
10.1016/j.therap.2021.05.004
复制
发表时间：
2021-07
期刊：
影响因子：
2.6
通讯作者：
Launay O
中科院分区：
文献类型：
--
作者：
Deplanque D;Launay O
严重急性呼吸系统综合征冠状病毒2型（SARS-CoV-2）在地球仪迅速传播，导致COVID-19大流行。为了减轻病毒对公共卫生和全球经济的影响，迅速开发了疫苗。在不到一年的时间里，按照通常的临床开发规则，几种疫苗已投放市场，并开展了大规模疫苗接种运动。在I期至III期临床试验期间，这些疫苗中的大多数已证明其安全性和有效性。尽管关于病毒变体的影响和免疫应答的持续时间仍存在问题，但基于信使RNA（mRNA）和腺病毒载体的疫苗在III期试验和真实的生活中均显示出70 - 95%的总体疗效。此外，所有这些疫苗也减少了疾病的严重形式，并可能对死亡率产生重大影响，从而可能改变大流行的进程。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread around the globe leading to the COVID-19 pandemic. To mitigate the effects of the virus on public health and the global economy, vaccines were rapidly developed. In less than one year, with respect to usual clinical development rules, several vaccines have been put on the market and mass vaccination campaigns have been deployed. During the phase I to phase III clinical trials, most of these vaccines have demonstrated both their safety and efficacy. Despite questions remain about the impact of virus variants and the duration of the immune response, messenger RNA (mRNA)-based and adenoviral vectored vaccines have demonstrated an overall efficacy from 70 to 95% in both phase III trials and real life. In addition, all these vaccines also reduce the severe forms of the disease and might strongly impact the mortality which could change the course of the pandemic.
登录
查看更多内容
影响因子：
82.9
作者：
Levine-Tiefenbrun, Matan;Yelin, Idan;Kishony, Roy
通讯作者：
Kishony, Roy
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1016/s0140-6736(21)00432-3
发表时间：
2021-03-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Costa Clemens SA;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Clutterbuck EA;Collins AM;Cutland CL;Darton TC;Dheda K;Dold C;Duncan CJA;Emary KRW;Ewer KJ;Flaxman A;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Galiza E;Goodman AL;Green CM;Green CA;Greenland M;Hill C;Hill HC;Hirsch I;Izu A;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Libri V;Lillie PJ;Marchevsky NG;Marshall RP;Mendes AVA;Milan EP;Minassian AM;McGregor A;Mujadidi YF;Nana A;Padayachee SD;Phillips DJ;Pittella A;Plested E;Pollock KM;Ramasamy MN;Ritchie AJ;Robinson H;Schwarzbold AV;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;White T;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1097/ede.0000000000001251
发表时间：
2020-11
期刊：
Epidemiology (Cambridge, Mass.)
影响因子：
--
作者：
Vandenbroucke JP;Brickley EB;Vandenbroucke-Grauls CMJE;Pearce N
通讯作者：
Pearce N
影响因子：
120.7
作者：
Stephenson, Kathryn E.;Le Gars, Mathieu;Barouch, Dan H.
通讯作者：
Barouch, Dan H.